Clinical Trials Logo

Clinical Trial Summary

This is a double-blind, placebo-controlled Phase 2 study to assess the efficacy, safety and tolerability of Glucagon RTU when administered to subjects with a history of bariatric surgery during episodes of post-postprandial hypoglycemia. Twelve eligible subjects will be randomly assigned to receive Glucagon RTU or placebo at the first of two clinical research center (CRC) visits, followed by the other treatment at the second CRC visit. Subjects will be randomly assigned to either Glucagon RTU or Placebo for the duration of a 12-week Outpatient Stage. A follow-up safety assessment visit will occur 14 to 28 days after a subject's last dose of study drug.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03770637
Study type Interventional
Source Xeris Pharmaceuticals
Contact
Status Completed
Phase Phase 2
Start date May 10, 2019
Completion date February 26, 2020

See also
  Status Clinical Trial Phase
Completed NCT03984370 - Dasiglucagon in the Treatment of Postprandial Hypoglycaemia After Roux-en-Y Gastric Bypass Phase 2
Recruiting NCT05597475 - GLP1R-imaging in Post-RYGB Hypoglycemia N/A
Completed NCT03103009 - Treatment Plan for an Individual Patient With Pasireotide for Hyperinsulinemic Hypoglycemia Phase 1
Completed NCT02685852 - Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia Phase 1
Completed NCT01933490 - Post-Gastric Bypass Hypoglycemia N/A
Completed NCT04836273 - Treatment of Post-bariatric Hypoglycaemia Phase 2
Recruiting NCT03930368 - Application of Raw Corn Starch on Patients With Insulinoma N/A